Dr. Abraham earned his MD from Harvard Medical School and completed post-graduate training in Internal Medicine, Cardiovascular Medicine, and Advanced Heart Failure/Transplant Cardiology at the University of Colorado. At Ohio State University, Dr. Abraham is a College of Medicine Distinguished Professor. He has been recognized as one of the “Best Doctors in America” for 18 consecutive years. His research has led to the approval/adoption of new heart failure therapies, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, baroreflex activation therapy, and mitral valve repair. He has authored more than 1,000 original works and been named a Clarivate Analytics Highly Cited Researcher and one of The World’s Most Influential Scientific Minds. He received the 2017 Distinguished Scientist Award from the American College of Cardiology.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease